Deco Medical Secures Tens of Millions in Series A Strategic Financing to Advance Hydrogel-Based Myocardial Repair Therapy for Heart Failure

VCBeat learned第一时间 that after months of efforts,Hangzhou Deke Medtech Co., Ltd. (hereinafter referred to as "Deke Medtech")Completed the first round of strategic financing. The amount of this round of financing is tens of millions of RMB.Exclusively invested by Tasly Capital Holding (Beijing) Co., Ltd., which will be mainly used to accelerate the research and development of innovative product pipelines and the progress of clinical trials, with the hope of expediting the application of hydrogel myocardial repair technology in the field of heart failure treatment.

Deke Medtech was registered and established in March 2017 in Binjiang District, Hangzhou. It is an innovative medical device R&D enterprise incubated by Denuo Medtech, dedicated to becoming a global leading innovative pioneer in the clinical treatment of heart failure using hydrogel myocardial repair technology.

Focusing on heart failure, a major category of cardiovascular diseases, Deke Medtech continues to deepen its expertise. Heart failure is characterized by high morbidity and high mortality rates, posing a significant threat to patients' life and health. Developing new technologies for the treatment of heart failure is urgently needed. Deke Medtech's XDROP^TMTranscatheter Endocardial Hydrogel Injection System

This round of investor Tasly Capital Holding (Beijing) Co., Ltd. has also reached a strategic cooperation intention with Deke Medtech. In the future, the two parties will carry out in-depth cooperation in multiple directions such as R&D, clinical, market, and investment in the field of heart failure that both parties focus on. In addition, Deke Medtech's R&D team has respectively cooperated with Xijing Hospital affiliated to Air Force Medical University and the National Engineering Research Center for Biomaterials of Sichuan University, further strengthening its innovative research capabilities.

Currently, Deke Medtech has already mastered the core technology of hydrogel for heart failure treatment and completed exploratory research. This year, it will carry out confirmatory clinical trials in more than ten top-tier tertiary hospitals across China, providing crucial supportive evidence for product market approval.

Dr. Nannan Shao, founder of Deke Medtech, stated"Thanks to Tasly Capital for its strong support in this round of financing. The field of heart failure treatment has huge market potential worldwide. Over the years, the company has been deeply engaged in the clinical application of hydrogel myocardial repair technology for heart failure. We will always adhere to our product advantages, refine product technology, and further promote the development of hydrogel implant therapy for heart failure."

Mr. Zhenjun Zi, founder of Deke Medtech, stated"Against the backdrop of the vigorous development and increasingly fierce competition in global cardiovascular medical innovation devices, Deke Medtech, as the world's first company to apply transcatheter endocardial injection hydrogel repair technology in the field of heart failure treatment, hopes to meet clinical needs, benefit more patients, and contribute to the treatment of heart failure."

Mr. Wang Chen, Senior Partner of Tasly Capital, stated"Deke Medtech, as a leading enterprise in hydrogel myocardial repair technology research, has already developed its own core technologies and R&D capabilities, bringing revolutionary advancements to the field of heart failure treatment. We are highly confident in the company's future development, technological innovation, and the expansion of its product pipeline. It is also an honor to have this round of financing from the venture capital firm, and we look forward to growing together with Deke Medtech and achieving great success."

Tasly Capital, relying on the industrial resources of its shareholder Tasly Holding Group, adheres to the concept of industrial investment and persists in the 4D investment strategy. It focuses on building an ecosystem for pharmaceuticals, medical devices, diagnostics, and digital health industries around disease areas such as cardiovascular, oncology, metabolism, and gastroenterology, while committing to assist startups and growth enterprises. Since its establishment in 2007, the company has managed a scale exceeding 10 billion RMB, with seven RMB funds and three USD funds successively; it has invested in over 100 projects cumulatively and exited more than 30 projects, including 16 IPOs; among them are well-known industry enterprises such as Innovent Biologics, Leadbiome, CARsgen Therapeutics, I-Mab, Berry Genomics, Xinwei Medical, and Northland Biotech.